ATE313333T1 - Verwendung eines leukämie-hemmenden faktor antagonisten - Google Patents

Verwendung eines leukämie-hemmenden faktor antagonisten

Info

Publication number
ATE313333T1
ATE313333T1 AT02016730T AT02016730T ATE313333T1 AT E313333 T1 ATE313333 T1 AT E313333T1 AT 02016730 T AT02016730 T AT 02016730T AT 02016730 T AT02016730 T AT 02016730T AT E313333 T1 ATE313333 T1 AT E313333T1
Authority
AT
Austria
Prior art keywords
leukemia
antagonist
factor antagonist
inhibiting factor
administered
Prior art date
Application number
AT02016730T
Other languages
English (en)
Inventor
Napoleone Ferrara
Kathleen King
Elizabeth A Luis
Jennie P Mather
Nicholas F Paoni
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE313333T1 publication Critical patent/ATE313333T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
AT02016730T 1995-04-24 1996-04-17 Verwendung eines leukämie-hemmenden faktor antagonisten ATE313333T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42738395A 1995-04-24 1995-04-24

Publications (1)

Publication Number Publication Date
ATE313333T1 true ATE313333T1 (de) 2006-01-15

Family

ID=23694642

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02016730T ATE313333T1 (de) 1995-04-24 1996-04-17 Verwendung eines leukämie-hemmenden faktor antagonisten
AT96913814T ATE233570T1 (de) 1995-04-24 1996-04-17 Verwendung des leukämie-inhibitor-faktor und endothelin antagonisten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT96913814T ATE233570T1 (de) 1995-04-24 1996-04-17 Verwendung des leukämie-inhibitor-faktor und endothelin antagonisten

Country Status (12)

Country Link
EP (2) EP0830143B1 (de)
JP (1) JPH11504332A (de)
AT (2) ATE313333T1 (de)
AU (1) AU702375B2 (de)
CA (1) CA2214636C (de)
DE (2) DE69626510T2 (de)
DK (2) DK1287832T3 (de)
ES (1) ES2254564T3 (de)
IL (1) IL117998A (de)
MX (1) MX9707939A (de)
WO (1) WO1996033740A1 (de)
ZA (1) ZA963274B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2333307A1 (en) 1998-07-06 2000-01-13 The Government Of The United States Of America As Represented By The Sec Retary, Department Of Health And Human Services Compositions and methods for in vitro fertilization
US20040131619A1 (en) * 2002-09-30 2004-07-08 Duke University Thymic atrophy
JP2011231014A (ja) * 2008-08-27 2011-11-17 Keiichi Fukuda 心不全の治療剤
EP2371860A1 (de) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Den humanen leukaemieinhibierenden Faktor (LIF) erkennender Antikörper und Verwendung von LIF-Antikörpern bei der Behandlung von Krankheiten im Zusammenhang mit ungewollter Zellproliferation
WO2018115960A1 (en) 2016-12-19 2018-06-28 Mosaic Biomedicals, S.L. Antibodies against lif and uses thereof
EP3555132B1 (de) 2016-12-19 2023-11-15 Medimmune Limited Antikörper gegen lif und verwendungen davon

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023556A1 (en) * 1992-05-08 1993-11-25 Genentech, Inc. Antibodies to leukemia inhibitory factor
WO1995008550A1 (en) * 1993-09-24 1995-03-30 Abbott Laboratories Endothelin antagonists

Also Published As

Publication number Publication date
EP1287832A2 (de) 2003-03-05
MX9707939A (es) 1997-12-31
DE69626510D1 (de) 2003-04-10
EP0830143B1 (de) 2003-03-05
CA2214636A1 (en) 1996-10-31
DE69635630D1 (de) 2006-01-26
DE69626510T2 (de) 2003-12-11
AU702375B2 (en) 1999-02-18
IL117998A0 (en) 1996-08-04
DE69635630T2 (de) 2006-08-10
DK1287832T3 (da) 2006-05-01
AU5665896A (en) 1996-11-18
ES2254564T3 (es) 2006-06-16
ZA963274B (en) 1997-10-24
DK0830143T3 (da) 2003-06-16
ATE233570T1 (de) 2003-03-15
WO1996033740A1 (en) 1996-10-31
JPH11504332A (ja) 1999-04-20
EP0830143A1 (de) 1998-03-25
CA2214636C (en) 2009-12-22
EP1287832A3 (de) 2003-04-16
IL117998A (en) 2001-04-30
EP1287832B1 (de) 2005-12-21

Similar Documents

Publication Publication Date Title
NO2013017I2 (no) (a)dekstrometorfan eller et farmasøytisk akseptabelt salt derav, for eksempel dekstrometorfanhydrobromid og (b) quinidin eller etfarmasøytisk akseptabelt salt derav, for eksempel quinidinsulfat
DK1616572T3 (da) Kimært anti-CD20-antistof, rituxan, til anvendelse i behandling af kronisk lymfatisk leukæmi
DK0445255T4 (da) Anvendelse af hyaluronsyre i kombination med ascorbinsyre, antitumormidler og/eller NSAID's til behandling af cancer
WO2001009138A3 (en) Chemokine receptor antagonists and methods of use therefor
DK0661973T3 (da) Fremgangsmåde til forebyggelse af NMDA-receptorkompleksmedieret neuronskade
MX9804597A (es) Derivados de bencimidazol sustituidos por naftilo como anticoagulantes.
DE59104440D1 (de) Epiduralkanüle.
CA2255714A1 (en) Improved phototherapeutic methods and devices for irradiating columnar environments
NO902444D0 (no) Polypeptider.
DE68920545D1 (de) Polyolefinlaminat mit hoher Festigkeit und hohem Elastizitätsmodul, das verbesserte Festkörper-Tiefziehfähigkeit aufweist.
IT8983533A0 (it) Dispositivo per la regolazione del frontale nei cassetti
ATE202599T1 (de) Mit isoliertem empfindlichem x-syndrom verbundene dns-sequenzen
ATE313333T1 (de) Verwendung eines leukämie-hemmenden faktor antagonisten
DK578887D0 (da) Antihypertensiva
DK0862454T3 (da) CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
NO990450L (no) Behandling av sinnslidelser
WO2001009119A3 (en) Chemokine receptor antagonists
BR0009644A (pt) Tratamento de carcinoma de célula renal
IT8819286A0 (it) Procedimento per il trattamento extracorporeo di liquido ascitico.
IT233634Y1 (it) Tavoletta filtro per cannule di gruppi di aspirazione dentistici.
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
ES8700940A1 (es) Procedimiento de obtencion de composiciones para el trata- miento de infecciones por rinovirus
ES1019711Y (es) hito de arista perfeccionado.
CO5170411A1 (es) Terapia para la leucemia mielocitica cronica
IT8403401A0 (it) Procedimento per l'intarsio con motivi ornamentali in metallo osimili di pannelli nobilitati con impiallacciatura in legno pregiato.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1287832

Country of ref document: EP

REN Ceased due to non-payment of the annual fee